Company profile
MIRA Pharmaceuticals, Inc.
NASDAQ: MIRA · Healthcare · Drug Manufacturers - General
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 56DQ —GM —SS 22
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$10.4M
Employees
2
as of 2026-08-20
Market cap
$32.4M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$10.4M-$10.4M2025
Total assets$11.1M$11.1M2025
Liabilities$702.1k$702.1k2025
Equity$10.4M$10.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is MIRA Pharmaceuticals, Inc.’s financial profile?
MIRA Pharmaceuticals, Inc. earned -$10.4M in FY2025 net income.
Peers · Healthcare
BetterLife Pharma Inc.——BriaCell Therapeutics Corp.——Obsidian Therapeutics Inc.——Lantern Pharma Inc.——Estrella Immunopharma, Inc.——LeonaBio, Inc.——Neighbors
Baltimore (Independent City) →Key facts
CEOErez Aminov
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersBaltimore, MD
ExchangeNASDAQ: MIRA
Employees2
IPO date2023-08-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.